Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
Go back to Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 18.71 +0.43 (2.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.28 | 52 Week High | $0.19 | |||
| Open | $18.12 | 52 Week Low | $0.07 | |||
| Day High | $18.81 | P/E | N/A | |||
| Day Low | $18.06 | EPS | $-0.01 | |||
| Volume | 6,619,073 | |||||
